Initial Characterization of Transgenic Mice Overexpressing Human Histamine H

Animals Gene Expression Heart / physiology Heart Rate / genetics Humans Mice Mice, Transgenic Myocytes, Cardiac / metabolism Organ Specificity Receptors, Histamine H2 / genetics Stroke Volume / genetics

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
04 2019
Historique:
received: 11 12 2018
accepted: 25 01 2019
pubmed: 8 2 2019
medline: 27 12 2019
entrez: 8 2 2019
Statut: ppublish

Résumé

In an integrative approach, we studied the role of histamine H

Identifiants

DOI: 10.1124/jpet.118.255711 PMID: 30728249
pubmed: 30728249
pii: jpet.118.255711
doi: 10.1124/jpet.118.255711
doi:

Substances chimiques

Receptors, Histamine H2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-141

Informations de copyright

Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

U Gergs (U)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

G Bernhardt (G)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

I B Buchwalow (IB)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

H Edler (H)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

J Fröba (J)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

M Keller (M)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

U Kirchhefer (U)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

F Köhler (F)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

N Mißlinger (N)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

H Wache (H)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.).

J Neumann (J)

Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (U.G., H.E., J.F., F.K., N.M., H.W., J.N.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (G.B., M.K.); Institute for Hematopathology, Hamburg, Germany (I.B.B.); and Institute for Pharmacology and Toxicology, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany (U.K.) joachim.neumann@medizin.uni-halle.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Système cardiovasculaire › Coeur › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Hémodynamique › Rythme cardiaque › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Cellules › Cellules musculaires › Myocytes cardiaques › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Phénomènes physiologiques › Spécificité d'organe › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs histaminergiques › Récepteur histaminergique H2 › Initial Characterization of Transgenic Mice...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Hémodynamique › Débit cardiaque › Débit systolique › Initial Characterization of Transgenic Mice...